ClinicalTrials.gg
RecruitingNCT06756490Updated Mar 9, 2026

A Phase I Study of HY-2003 in the Subjects With Excessive Submental Fat Accumulation

A Phase 1 interventional study of HY-2003 (10 mg/ml), BELKYRA and placebo and HY-2003 (5 mg/ml) and placebo in Moderate or Severe Submental Fullness, sponsored by Sichuan Huiyu Pharmaceutical Co., Ltd. Recruiting at 2 sites in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-09.

Sponsored by Sichuan Huiyu Pharmaceutical Co., Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 147 studies in Lymphoma, Follicular with a site in China — 75 open to participants now, 88 under way, 20 of them phase 3. Lymphoma, Follicular · China.

Planned enrollment
101st of 132
30 · median 93
Started
2024
with 16 others
Phase 1
20 of 147
10 open now
Primary completion
2026-12
later than 23 of 87 live
Registered
104th of 147
by date

Among the 147 studies in Lymphoma, Follicular with a site in China, this one is the 101st largest by planned enrollment of the 132 interventional ones that give a count, is one of 17 that started in 2024, is one of 20 in phase 1, reaches primary completion later than 23 of the 87 other live ones, and was the 104th registered.

Lymphoma, Follicular

1,893 studies on the registry are indexed under Lymphoma, Follicular; 290 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

75 of the 147 studies in Lymphoma, Follicular with a site in China are open now. Recruiting first, the newest first:

70 more — sign in →

All 75 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 226 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies in Lymphoma, Follicular with a site in China, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the safety of HY-2003 in subjects with moderate to severe submental fat accumulation at different doses and dosing frequencies in comparison with the positive control and placebo. The secondary objectives include: Evaluating the pharmacokinetic characteristics of HY-2003 after a single administration in humans and obtaining preliminary pharmacokinetic parameters; Evaluating the efficacy of HY-2003 under different doses and dosing frequencies, compared with the positive control and placebo, in the treatment of subjects with moderate to severe submental fat accumulation.

03

Conditions studied

  • Moderate or Severe Submental Fullness
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Fully understand the requirements of the trial, and signed the form voluntarily;
  2. The subjects should have good compliance, are able to fully understand this clinical trial, have reasonable expectations for the injection effects, and can abide by the research procedures until the end of the clinical trial.
  3. Aged 18 to 65 years (including boundary values), male or female.
  4. At screening and baseline, the investigator rated moderate to severe submental outline protrusion due to submental fat accumulation according to the clinician-reported Submental Fat Rating Scale (CR-SMFRS), i.e., those with a score of 2 to 3 points.
  5. Sufficient submental fat to allow for safe subcutaneous fat layer injections (at least 25 injections can be completed), as judged by the investigator.
  6. Stable body weight for at least 6 months prior to Screening.
  7. Vital sign examinations, physical examinations, clinical laboratory examinations (blood routine, urine routine, blood biochemistry, infectious disease screening, coagulation function, pregnancy test (for females), drug screening, etc.), and 12-lead examinations, with the results showing no abnormalities or having abnormalities but judged by the researcher as being of no clinical significance.
  8. Subjects had no pregnancy plans and voluntarily take effective measures during the screening period and within 6 months after the last dose, and have no sperm or egg donation plans.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who have previously undergone surgical operations, liposuction treatments in the submental area that may affect the implementation and/or evaluation of the study, or have been injected with lipolytic drugs similar to the study drugs (for example, phosphatidylcholine, etc.).
  2. Subjects who have had previous allergic reactions to deoxycholic acid or other components of the drug.
  3. History of to topical or local anesthetics (e.g., lidocaine, benzocaine, procaine, etc.).
  4. Subjects with a history of prior surgery in the chin or neck region; or significant submental scarring, infection, cancerous or precancerous lesions, and/or unhealed wounds, mandibular retrusion (a mandibular retrusion malocclusion caused by mandibular hypoplasia or congenital absence of lower anterior teeth and lateral pterygoid insufficiency) that could affect the evaluation results as assessed by the investigator.
  5. Subjects with chin and neck skin diseases, or with a keloid-forming tendency (with a previous tendency of scar hyperplasia or keloid), which may affect the efficacy evaluation or subject safety as judged by the investigator.
  6. Subjects who have received previous lipolytic therapy with poor efficacy or serious adverse reactions.
  7. Platissimus muscle protrusion at rest, as judged by the investigator, impacts assessment of submental fat status.
  8. Including but not limited to Madelung's disease (benign symmetric lipomatosis) which leads to an increase in local fat in the neck area and needs to be excluded as judged by the investigator.
  9. (BMI) less than 17 or greater than 40 kg/m2 (excluding borderline) at screening.
  10. Current or past dysphagia.
  11. Subjects with very severe laxity of the submental skin as judged by the investigator.
  12. Enlargement of the submental area was found to be due to other causes rather than local excessive submental fat accumulation.
  13. Subjects who have used drugs that can prolong the clotting time (for example, aspirin, non-steroidal anti-inflammatory drugs, clopidogrel, warfarin, etc.) within 2 weeks before screening, or who need to take any drugs with anticoagulant functions (including but not limited to warfarin, heparin) during the trial.
  14. Subjects who have used topical drugs (such as , tretinoin ointment) on the submental skin within 1 month before screening, or who are expected to need to use these drugs on the submental area during the research process (until 12 weeks after the completion of the last injection).
  15. Subjects who have donated blood (including blood components) or suffered from massive blood loss (≥200 mL) within 3 months before screening.
  16. Subjects who smoked more than 5 cigarettes per day within 3 months before screening, or who were unable to stop using any tobacco products during the PK blood sampling period.
  17. Subjects who consumed more than 14 units of alcohol per week within 3 months before screening (1 unit of alcohol is approximately equivalent to 360 mL of beer, 45 mL of spirits with an alcohol content of 40%, or 150 mL of wine), or who were unable to abstain from alcohol during the PK blood sampling period.
  18. Subjects who consumed any food or beverage containing caffeine or that can produce caffeine after metabolism (such as coffee, tea, chocolate) within 48 hours before drug administration; or those who did not agree to refrain from consuming such food or beverage during the PK blood sampling period.
  19. Subjects who participated in any other drug clinical trials and received drug treatment within 3 months before screening.
  20. Subjects with a history of drug abuse within 6 months before screening or who used drugs within 3 months before screening.
  21. Subjects who received ultrasonic scalpel, radiofrequency, laser surgery, chemical peeling or skin fillers (such as hyaluronic acid) treatment for the neck or submental area within 12 months before screening, or who received botulinum toxin injection treatment for the neck or submental area within 6 months before screening; or who received non-invasive skin tightening treatment within 6 months before screening.
  22. According to the researcher's judgment, the dissolution of submental fat would cause submental skin laxity or have other anatomical features (for example, protrusion of the subplatysmal fat, skin laxity in the neck or chin area, protrusion of the platysma band), resulting in an unacceptable cosmetic effect.
  23. At the time of enrollment screening, the results of coagulation function tests, including (PT) and activated partial thromboplastin time (APTT), showed bleeding abnormalities of clinical significance.
  24. Subjects who cannot tolerate venipuncture, have a history of fainting due to needles or blood, or have significant abnormal clinical manifestations.
  25. Subjects with diseases that require exclusion due to significant abnormal clinical manifestations, including but not limited to diseases of the nervous system, cardiovascular system, blood and lymphatic system, immune system, kidneys, liver, gastrointestinal tract, respiratory system, metabolism, skeletal system and other systems.
  26. Subjects suffering from any diseases that may interfere with the safety assessment of the trial or affect the normal conduct of the clinical trial by the subjects or the signing of the form.
  27. Subjects whose participation in the trial may increase their risks or who may have other severe, acute or chronic diseases that may interfere with the interpretation of the trial results and are judged by the researcher as not suitable for participating in the clinical trial.
  28. Subjects who plan to undergo any surgeries or take any drugs that may lead to significant changes in body weight (≥10%) during the study period (for example, systemic corticosteroids, weight-loss drugs, bariatric surgeries).
  29. Subjects with infectious diseases before screening, such as syphilis, AIDS, , etc.
  30. Female subjects with potential fertility who are pregnant, breastfeeding, planning to become pregnant or not taking reliable measures, and who are unwilling to adopt reliable contraceptive methods (for example: transdermal patches, intrauterine devices/systems (IUD/IUS), oral/implanted or injected contraceptives, abstinence and vasectomy of their spouses) during the participation in the trial.
  31. Subjects with other comorbidities that may interfere with the research assessment only as judged by the researcher, or subjects who are considered by the researcher as facing greater risks due to participation in the study.
  32. Subjects judged by the researcher as not suitable for participating in this trial for other reasons.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Group A - Subjects will be randomly assigned to three subgroups

    Drug: HY-2003 (10 mg/ml), BELKYRA and placebo

  • Experimental
    Group B - Subjects will be randomly assigned to two subgroups

    Drug: HY-2003 (5 mg/ml) and placebo

  • Experimental
    Group C - Subjects will be randomly assigned to two subgroups

    Drug: HY-2003 (5 mg/ml) and placebo

Interventions

  • DrugHY-2003 (10 mg/ml), BELKYRA and placebo

    Participants received HY-2003 (10 mg/ml), or BELKYRA, or placebo administered up to 10 mL per treatment session at intervals of approximately 4 weeks for up to a maximum of 6 treatments.

  • DrugHY-2003 (5 mg/ml) and placebo

    Participants received HY-2003 (5 mg/ml) or placebo administered up to 10 mL per treatment session at intervals of approximately 2 weeks for up to a maximum of 6 treatments.

  • DrugHY-2003 (5 mg/ml) and placebo

    Participants received HY-2003 (10 mg/ml) or placebo administered up to 10 mL per treatment session at intervals of approximately 4 weeks for up to a maximum of 6 treatments. It is possible to explore the maximum number of administrations exceeding six treatment sessions.

06

What researchers measure

Primary outcomes

  1. The occurrence of all adverse events; The occurrence of adverse events at the injection site; Laboratory tests, vital signs, physical examinations, 12-lead electrocardiograms.

    Time frame: During the intervention

  2. Pain scores evaluated by the Visual Analogue Scale (VAS,0~10mm,the longer the length means a worse outcome)

    Time frame: During the intervention

  3. The scores of submental skin laxity evaluated by the Submental Skin Laxity Grade (SMSLG, 0~4 points, the higher score means a worse outcome)

    Time frame: Four weeks and twelve weeks after the last treatment.

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Dec 2026, 23 months after the start.

Of 85 industry-sponsored phase 1 interventional studies under Lymphoma, Follicular, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 71. This study's planned 23 months is below that.

Counting every sponsor, half of 174 studies reached it within 51 months; a quarter within 30 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2024
First posted
Jan 3, 2025
StartActual
Dec 26, 2024
Primary completionEst.
Dec 6, 2026
CompletionEst.
May 31, 2027
Last update
Mar 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06756490
Responsible party
Sponsor
First posted
Jan 3, 2025
Start date
Dec 26, 2024
Primary completion
Dec 6, 2026 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Mar 9, 2026

Study contacts

Chun Wan
Contact
chun.wan3717@huiyupharma.com
028-86021875

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion